Additionally, other trials are recruiting participants for the treatment of head and neck squamous cell carcinoma and malignant solid neoplasm with Alisertib in combination with Pembrolizumab (NCT04555837), and non-small-cell lung cancer (NCT04479306) and EGFR-mutant lung cancer (NCT04085315) with Alisertib in combination with Pembrolizumab. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.